BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25257528)

  • 1. SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.
    Du Y; Lu F; Li P; Ye J; Ji M; Ma D; Ji C
    Int J Mol Sci; 2014 Sep; 15(9):17065-76. PubMed ID: 25257528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia.
    Agrawal S; Hofmann WK; Tidow N; Ehrich M; van den Boom D; Koschmieder S; Berdel WE; Serve H; Müller-Tidow C
    Blood; 2007 May; 109(9):3895-905. PubMed ID: 17234736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patients.
    Tao YF; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Xu LX; Li ZH; Wang NN; Du XJ; Sun LC; Zhao H; Fang F; Su GH; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
    Int J Mol Med; 2014 Dec; 34(6):1505-15. PubMed ID: 25319049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
    Schmelz K; Wagner M; Dörken B; Tamm I
    Int J Cancer; 2005 May; 114(5):683-95. PubMed ID: 15609309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML).
    Yan-Fang T; Jian N; Jun L; Na W; Pei-Fang X; Wen-Li Z; Dong W; Li P; Jian W; Xing F; Jian P
    BMC Med Genet; 2013 Jul; 14():74. PubMed ID: 23870168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
    Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
    Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
    Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
    Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decitabine activates specific caspases downstream of p73 in myeloid leukemia.
    Tamm I; Wagner M; Schmelz K
    Ann Hematol; 2005 Dec; 84 Suppl 1():47-53. PubMed ID: 16193303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia.
    McLornan D; Hay J; McLaughlin K; Holohan C; Burnett AK; Hills RK; Johnston PG; Mills KI; McMullin MF; Longley DB; Gilkes A
    Br J Haematol; 2013 Jan; 160(2):188-98. PubMed ID: 23167276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.
    Tao YF; Xu LX; Lu J; Hu SY; Fang F; Cao L; Xiao PF; Du XJ; Sun LC; Li ZH; Wang NN; Su GH; Li YH; Li G; Zhao H; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Zhu XM; Ni J; Wang J; Xing F; Zhao WL; Pan J
    J Exp Clin Cancer Res; 2015 Jan; 34(1):4. PubMed ID: 25609158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
    Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
    Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML.
    Larmonie NSD; Arentsen-Peters TCJM; Obulkasim A; Valerio D; Sonneveld E; Danen-van Oorschot AA; de Haas V; Reinhardt D; Zimmermann M; Trka J; Baruchel A; Pieters R; van den Heuvel-Eibrink MM; Zwaan CM; Fornerod M
    Oncogene; 2018 Jan; 37(1):107-115. PubMed ID: 28892045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia.
    Lian XY; Ma JC; Zhou JD; Zhang TJ; Wu DH; Deng ZQ; Zhang ZH; Li XX; He PF; Yan Y; Lin J; Qian J
    J Cell Physiol; 2019 Jun; 234(6):9438-9446. PubMed ID: 30317626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
    Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
    Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia.
    Yang J; Xiao X; Li R; Li Z; Deng M; Zhang G
    Cancer Biomark; 2016; 16(1):81-8. PubMed ID: 26835708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancer.
    Liu WB; Jiang X; Han F; Li YH; Chen HQ; Liu Y; Cao J; Liu JY
    Cell Death Dis; 2013 Oct; 4(10):e882. PubMed ID: 24157876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia.
    Zhang X; Zeng J; Zhou M; Li B; Zhang Y; Huang T; Wang L; Jia J; Chen C
    Mol Cancer; 2012 Aug; 11():56. PubMed ID: 22900969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways.
    Wang LQ; Wong KY; Rosèn A; Chim CS
    Oncotarget; 2015 Dec; 6(42):44422-36. PubMed ID: 26517243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia.
    He PF; Xu ZJ; Zhou JD; Li XX; Zhang W; Wu DH; Zhang ZH; Lian XY; Yao XY; Deng ZQ; Lin J; Qian J
    J Cell Physiol; 2018 Sep; 233(9):6604-6614. PubMed ID: 29150948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.
    Röhrs S; Dirks WG; Meyer C; Marschalek R; Scherr M; Slany R; Wallace A; Drexler HG; Quentmeier H
    Mol Cancer; 2009 Oct; 8():86. PubMed ID: 19835597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.